Articles

Medicines safety update - important information for health professionals

Medicines Safety Update - Information for health professionals

Medicines Safety Update - Information for health professionals

Acellur Dermal Matrix Products used in Breast Reconstruction - clarification on reports of potential higher complication rates.

Medicines Safety Update - Information for health professionals

Medical device safety update regarding pulse oximeters limitations, including the effect of skin pigmentation.

Medicines Safety Update - Information for health professionals

Medicines Safety Update - Information for health professionals

The TGA is aware that, in Europe, atrioventricular blocks have been reported in patients receiving high doses of continuous intravenous infusion of octreotide and in patients receiving bolus octreotide intravenously.

Health professionals are advised that the Product Information for pentosan polysulfate sodium has been updated with a warning about potential pigmentary maculopathy, especially after long-term use.

Medicines Safety Review

Medicines Safety Review

Product Information documents for parenteral iron products are currently being updated to include information about fetal bradycardia and Kounis syndrome.

The Product Information for nifedipine has been updated to provide new information about the risk of acute pulmonary oedema when used as a tocolytic agent (inhibiting myometrial smooth muscle contractions) for the treatment of preterm labor in pregnancy.

The Product Information for ocrelizumab has been updated to include a warning and further information about late onset neutropenia.

Health professionals are advised that the Product Information (PI) documents for methylphenidate products have been updated with new information about use in pregnancy.

Information for health professionals

Health professionals are advised that the Product Information (PI) documents for combined oral contraceptives containing dienogest have been updated to include more detailed information on the risk of venous thromboembolism.

Health professionals are advised that the Product Information (PI) documents for sertraline have been updated to include microscopic colitis as a potential adverse effect of unknown frequency based on post-marketing experience.

The recommended duration of contraception after finishing tamoxifen treatment has been extended from two months to nine months.

Consumer goods with button batteries

Medicines Safety Update article

Medicines Safety Update article

Clinicians need to tailor the device programming of CRT-D devices to each patient to ensure the delivery of therapy

Ethyl chloride spray should not be used in association with medical devices containing a common plastic